Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
LLY Analyst Ratings As of June 2026, Barchart analyst ratings for LLY shares show an unusually strong consensus: 26 out of 30 analysts recommend Buy, while the remaining 4 rate the stock as Hold
Consistency remains the gold standard for metabolic health
By month three, a clear separation emerges, with compounded users demonstrating significantly lower continuation rates
Novo Nordisk testing found over 24% impurities in some compounded samples, underscoring that compounded medications don't undergo the same level of purity validation as FDA-approved products
The article calls it rare but possible
US$ 29.68
US$ 20.11
US$ 26.25
US$ 27.48
US$ 28.22
US$ 21.16
![Roots of All Evil (Schemes) [Archenemy Schemes] 98b](https://cdn.shopify.com/s/files/1/0824/7345/1830/products/7ce23999-5166-566c-93f0-bcae05aa6582_4cc6bb9a-f36b-4265-92bb-5da4aa953e57.jpg?v=1697580730)
